Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: Recommendations for prevention and treatment

被引：26

作者：

Fehm, T. ^{[1
]}

Felsenberg, D. ^{[2
,3
]}

Krimmel, M. ^{[4
]}

Solomayer, E. ^{[1
]}

Wallwiener, D. ^{[1
]}

Hadjii, P. ^{[4
,5
]}

机构：

[1] Univ Womens Hosp Tubingen, D-72076 Tubingen, Germany

[2] Free Univ Berlin, Ctr Muscle & Bone Res, Charite, D-12203 Berlin, Germany

[3] Humboldt Univ, D-12203 Berlin, Germany

[4] Univ Tubingen Hosp, Dept Oral & Maxillofacial Surg, D-72076 Tubingen, Germany

[5] Univ Marburg, Dept Gynaecol Endocrinol Reprod Med & Osteoporosi, D-35033 Marburg, Germany

来源：

BREAST | 2009年 / 18卷 / 04期

关键词：

Breast cancer; Bisphosphonates; Bone metastases; Osteonecrosis of the jaw; PLUS ZOLEDRONIC ACID; ADJUVANT THERAPY; FOLLOW-UP; POSTMENOPAUSAL WOMEN; AMERICAN-SOCIETY; RISK-FACTORS; BONE LOSS; METASTASES; GUIDELINES; MANAGEMENT;

D O I：

10.1016/j.breast.2009.07.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Osteonecrosis of the jaw (ONJ) is a rare but severe disease which has been diagnosed in women with breast cancer on a bisphosphonate (BP) therapy. Thus, the German society of senology appointed a multidisciplinary task force to establish a consensus on the use of bisphosphonates in breast cancer patients with bone metastases, considering in particular the possible risk of ONJ. This report summarizes the results and recommendations for the prevention and treatment of ONJ in breast cancer patients receiving BP. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：213 / 217

页数：5

共 38 条

[1]

Guidance on the use of bisphosphonates in solid tumours:: recommendations of an international expert panel [J].